Orforglipron Tablets

In the clinical practice of blood glucose control and weight management of obese or overweight adults with type 2 diabetes, patient compliance is still the biggest variable whether treatment can produce actual effect, and injection is one of its main obstacles. Kpeptide's orforglipron tablets are a once daily oral small molecule GLP-1 receptor agonist that breaks through the delivery limitations of traditional injectable GLP-1 drugs. Convenience and efficacy are no longer a trade-off, and patients can better receive treatment in the long term.

Compared with other oral peptide formulations, the advantages of this solution are clear and quantifiable: Higher bioavailability; Stronger inter batch consistency and greater supply elasticity; The lower overall cost provides wider accessibility for patients and greater space for channel profits.For partners, Kpeptide delivers more than a product - it offers an end-to-end solution covering development, registration, supply, and market launch. Through rigorous quality management, dependable delivery commitments, and transparent technical communication, we respond to the real questions you face at every step - from process validation to regulatory filing, from inventory planning to clinical feedback.

Research on additional potential applications of ogerlon is ongoing. Such investigational areas should not be interpreted as approved indications.

 

At present, orforglipron tablets have entered Phase III clinical trials for the treatment of peripheral vascular diseases (PVD). Multiple early studies and trial designs have preliminarily validated their application potential in this field, with the most concentrated research focused on Fontaine Stage II peripheral artery disease (PAD), mainly presenting as intermittent claudication. This is the most common clinical stage of PVD, in which patients experience severely impaired quality of life yet lack effective metabolic interventions.

 

The ongoing Phase III trial is designed as a randomized, double‑blind, placebo‑controlled study. It plans to enroll 1,205 patients globally, including 120 at Chinese sites, with an approximate duration of 58 weeks. The trial primarily evaluates the efficacy and safety of once‑daily oral tab in patients with PAD.The primary endpoint is the percentage change in maximum walking distance. Secondary endpoints include changes in pain‑free walking distance, VascuQoL‑6 score (vascular disease quality of life), 6‑minute walking distance, high‑sensitivity C‑reactive protein, and systolic blood pressure, comprehensively covering core therapeutic goals: symptom improvement, vascular function recovery, and inflammation control.During the trial, patients receive oral this med with titration up to a maximum dose of 36 mg, compared with placebo or standard care. Efficacy is further assessed using imaging examinations such as the ankle‑brachial index (ABI) and patient‑reported outcomes (PRO).

 

Early clinical studies and relevant meta‑analyses have provided strong support for the Phase III trial. Research shows that it exerts significant weight reduction, glycemic control, and lipid‑modulating effects. At the highest dose, patients achieved an average weight reduction of 12.4% over 72 weeks, and a maximal HbA1c reduction of 2.2%, superior to oral semaglutide. It also significantly improves the lipid profile and reduces the accumulation of atherosclerotic risk factors.Furthermore, preclinical studies indicate that this can improve vascular endothelial function, reduce vascular inflammation, effectively delay the formation and progression of atherosclerotic plaques, and lower the risk of peripheral vascular occlusion. It is particularly suitable for PVD patients with comorbid diabetes and obesity-high‑risk populations often poorly responsive to conventional therapies. The multi‑metabolic regulatory effects of it achieve a "one‑drug, multiple‑benefits" strategy, simultaneously managing underlying metabolic diseases and vascular lesions.

 

Based on its mechanism of action and clinical development, it have well‑defined application scenarios in PVD, especially in patients with metabolic disorders, providing complementary benefits to existing treatments and optimizing therapeutic regimens.

First‑line adjuvant therapy for PVD patients with comorbid diabetes/obesityApproximately 60% of PVD patients have diabetes or obesity. In these patients, atherosclerosis progresses faster, limb ischemia is more severe, and conventional therapies rarely control both metabolic disorders and vascular disease simultaneously.

 

As an oral formulation, orforglipron tablets improve glycemic control and reduce weight while exerting vascular protective effects, delaying disease progression and lowering the risk of limb ulcers, gangrene, and cardiovascular adverse events. Compared with injectable GLP‑1 drugs, its convenience greatly improves long‑term adherence, making it a suitable long‑term adjuvant option. Clinical data confirm superior glycemic and weight control versus oral semaglutide, along with improved lipid metabolism and further reduction of atherosclerotic risk, offering comprehensive protection for high‑risk patients.

 

Postoperative adjuvant rehabilitation therapy for PVDSevere PVD often requires interventional therapy (e.g., balloon angioplasty, stenting) or surgical bypass grafting. However, postoperative issues such as restenosis and exacerbated inflammation remain major challenges.It can reduce the risk of postoperative restenosis, promote vascular function recovery, control metabolic risk factors including blood glucose and body weight, improve rehabilitation quality, and lower recurrence rates by suppressing inflammation, improving endothelial function, and regulating metabolic disorders. Its oral formulation avoids injection difficulties in patients with limited limb mobility, further enhancing convenience and adherence.

 

Alternative therapy for patients intolerant to injectable agentsTraditional GLP‑1 therapies are mostly injectable. Some PVD patients struggle with long‑term injection due to limb ischemia, limited mobility, or injection aversion, leading to treatment interruptions and disease recurrence.As the world's first oral small‑molecule non‑peptide GLP‑1 receptor agonist in late‑stage clinical development, it completely overcome the limitations of injection. Once‑daily oral administration requires no professional procedure and allows self‑medication, effectively solving the pain points of injectable therapy. Kpeptide provides a viable option for patients intolerant to injections, improving adherence and ensuring treatment continuity.

The data and information in this section are sourced from:

Frias J, Blevins T, et al. Efficacy and safety of oral orferglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet, 2023, 402(10400): 472-483.
Kawai T, Sun B, Yoshino H, et al. Structural basis for GLP-1 receptor activation by orferglipron (LY3502970), an orally active nonpeptide agonist. Proc Natl Acad Sci U S A, 2020, 117(47): 29959-29967.
Ma X, Liu R, Pratt EJ, et al. Effect of food consumption on the pharmacokinetics, safety, and tolerability of once-daily orferglipron (LY3502970). Diabetes Ther, 2024, 15(4): 819-832.

Peripheral vascular disease (PVD) is a highly prevalent chronic disease, and there are still a large number of unmet clinical needs: limited drug options, insufficient long-term patient compliance, and difficulty in synchronously managing multiple risk factors. Market forecasts show that by 2030, the global market size for peripheral vascular disease treatment is expected to exceed $30 billion.

As a new oral GLP-1 receptor agonist, ogerlon brought by Kpeptide has the characteristics of pleiotropy, convenience and good safety. It is expected to fill the gap in the field of metabolic targeted treatment of peripheral vascular diseases, reshape the existing treatment pattern, especially for patients with diabetes and obesity, showing broad clinical application prospects.

Currently, phase III clinical trials for peripheral vascular disease, ogerlon including those in China, are underway and are expected to be completed and results announced by 2028. If the trial is successful, the drug is expected to be approved for the treatment of peripheral arterial disease (PAD) in 2027-2028, becoming the first GLP-1 receptor agonist primarily used for PAD, further expanding its clinical application range and benefiting more patients.

With good sales performance in Russia, Saudi Arabia, the United Kingdom, South Korea, Taiwan, China, Türkiye, Singapore and other markets, Kpeptide has accumulated a wide range of real world drug experience, laying a solid foundation for the global expansion of products.

Testing Team

Delivery packaging

Production workshop

 

Click to learn more

In the production process of this product, Kpeptide have established a dedicated production line and equipped a professional technical team and sales team to provide services. Partial display has been made in the above figure. For more information about production, services, and qualifications, please click the button for detailed understanding.

Hot Tags: orforglipron tablets, China orforglipron tablets manufacturers, suppliers, salcatonin injection, intranasal desmopressin acetate, best glp 1 peptide, unicalcin 100, glp1 shot, etelcalcetide structure